Published in Eur Arch Otorhinolaryngol on January 11, 2011
Clinical predictors for response to proton pump inhibitor treatment in patients with globus. J Neurogastroenterol Motil (2013) 0.82
Prevalence of voice & swallowing complaints in Pre-operative thyroidectomy patients: a prospective cohort study. J Otolaryngol Head Neck Surg (2014) 0.77
Impact of laryngopharyngeal reflux on subjective and objective voice assessments: a prospective study. J Otolaryngol Head Neck Surg (2016) 0.75
TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial. Trials (2016) 0.75
Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol (2004) 3.15
Validity and reliability of the reflux symptom index (RSI). J Voice (2002) 3.02
The validity and reliability of the reflux finding score (RFS). Laryngoscope (2001) 2.88
Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope (2006) 2.17
Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg (2008) 1.91
Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg (2002) 1.88
Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. Am J Gastroenterol (1997) 1.74
Omeprazole for the treatment of posterior laryngitis. Am J Med (1994) 1.56
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope (2005) 1.38
Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg (2004) 1.26
Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery (1998) 1.21
Laryngopharyngeal reflux: More questions than answers. Cleve Clin J Med (2010) 1.12
Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope (2006) 0.96
Trends in laryngopharyngeal reflux: a British ENT survey. Eur Arch Otorhinolaryngol (2007) 0.88
Ambulatory pH monitoring methodology. Ann Otol Rhinol Laryngol Suppl (2000) 0.87
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther (2010) 0.87
Outcomes of acid suppressive therapy in patients with posterior laryngitis. Otolaryngol Head Neck Surg (2001) 0.87
Gastroesophageal reflux and laryngopharyngeal reflux in patients with sleep-disordered breathing. Otolaryngol Head Neck Surg (2006) 0.86
Hoarseness: is it really laryngopharyngeal reflux? Laryngoscope (2008) 0.86
Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope (2005) 0.86
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol (2003) 0.86
Laryngopharyngeal reflux: diagnosis and treatment of a controversial disease. Curr Opin Allergy Clin Immunol (2008) 0.82
Development and validation of a laryngopharyngeal reflux questionnaire, the Pharyngeal Reflux Symptom Questionnaire. Scand J Gastroenterol (2010) 0.80
Laryngopharyngeal reflux: a prospective analysis of a 34 item symptom questionnaire. Clin Otolaryngol (2009) 0.79
Efficacy of once-daily esomeprazole treatment in patients with laryngopharyngeal reflux evaluated by 24-hour pH monitoring. Otolaryngol Head Neck Surg (2007) 0.78
Medical therapy of reflux laryngitis. J Clin Gastroenterol (2008) 0.77
Assessment of laryngopharyngeal reflux: facts. Surgeon (2007) 0.75
Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother (2004) 0.75
Flexible laryngoscopy-guided pharyngeal pH monitoring in infants. Laryngoscope (2007) 0.75
Echinococcosis of the liver. Abdom Imaging (2008) 1.88
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) (2006) 1.77
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
Zinc deficiency may be a cause of burning mouth syndrome as zinc replacement therapy has therapeutic effects. J Oral Pathol Med (2010) 1.55
Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. J Control Release (2010) 1.51
[Gene expression profiling using oligonucleotide microarray in atrophic gastritis and intestinal metaplasia]. Korean J Gastroenterol (2007) 1.47
A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl (2008) 1.43
Mesenchymal neoplasms of the major salivary glands: clinicopathological features of 18 cases. Eur Arch Otorhinolaryngol (2007) 1.41
Basal cell adenocarcinoma of the salivary gland: a morphological and immunohistochemical comparison with basal cell adenoma with and without capsular invasion. Diagn Pathol (2013) 1.39
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest (2016) 1.39
18F-FDG PET/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas. Clin Nucl Med (2017) 1.39
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) (2005) 1.35
Safety and efficacy of fast-track surgery in laparoscopic distal gastrectomy for gastric cancer: a randomized clinical trial. World J Surg (2012) 1.31
Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol (2008) 1.30
Metastatic carcinomas to the oral cavity and oropharynx. Korean J Pathol (2012) 1.27
Solitary fibrous tumor of the parapharyngeal space: MR imaging findings. AJNR Am J Neuroradiol (2002) 1.24
Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release (2007) 1.18
Heparin-coated gold nanoparticles for liver-specific CT imaging. Chemistry (2009) 1.17
Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol (2008) 1.15
Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol (2012) 1.14
Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol (2007) 1.11
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials (2012) 1.10
N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J Control Release (2006) 1.09
Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.07
Prevalence of otolaryngologic diseases in South Korea: data from the Korea national health and nutrition examination survey 2008. Clin Exp Otorhinolaryngol (2010) 1.06
Prognostic value of lymph node density in node-positive patients with oral squamous cell carcinoma. Ann Surg Oncol (2011) 1.03
Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med (2007) 1.01
Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck (2011) 1.01
Secondary rhinoplasty of the Asian nose: correction of the contracted nose. Aesthetic Plast Surg (2004) 1.00
Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med (2013) 1.00
Wnt signaling controls radiosensitivity via cyclooxygenase-2-mediated Ku expression in head and neck cancer. Int J Cancer (2008) 1.00
A cadaveric analysis of the ideal costal cartilage graft for Asian rhinoplasty. Plast Reconstr Surg (2004) 0.99
Facial nerve schwannomas: different manifestations and outcomes. Surg Neurol (2004) 0.98
Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk. J Korean Med Sci (2006) 0.98
Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med (2007) 0.98
18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract. Oral Oncol (2007) 0.96
The clinical usefulness of (18)F-FDG PET/CT for the evaluation of lymph node metastasis in periorbital malignancies. Korean J Radiol (2009) 0.96
Radiotherapy for esthesioneuroblastoma: is elective nodal irradiation warranted in the multimodality treatment approach? Int J Radiat Oncol Biol Phys (2010) 0.95
Cervical sensory preservation during neck dissection. Oral Oncol (2006) 0.94
In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials (2007) 0.94
Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells. Exp Mol Med (2005) 0.94
Knockdown of β-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal (2012) 0.94
Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol (2006) 0.94
Methane emission and dynamics of methanotrophic and methanogenic communities in a flooded rice field ecosystem. FEMS Microbiol Ecol (2014) 0.94
Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release (2006) 0.94
Comparative Analysis of Efficiency of Injection Laryngoplasty Technique for with or without Neck Treatment Patients: A Transcartilaginous Approach Versus the Cricothyroid Approach. Clin Exp Otorhinolaryngol (2010) 0.94
MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm (2007) 0.94
Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol (2008) 0.93
The effect of electrical stimulation therapy on dysphagia following treatment for head and neck cancer. Oral Oncol (2008) 0.93
Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol (2013) 0.93
Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg (2013) 0.93
Risk factors of surgical site infection in patients undergoing major oncological surgery for head and neck cancer. Oral Oncol (2011) 0.92
Quality of life and voice in patients after laser cordectomy for Tis and T1 glottic carcinomas. Head Neck (2007) 0.91
Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma. Ann Surg Oncol (2011) 0.91
Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol (2013) 0.90
Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol (2009) 0.90
Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways. PLoS One (2012) 0.90
The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol (2008) 0.90